advances in hematopoietic stem cell mobilization and peripheral blood stem cell transplantation
Authors
abstract
hematopoietic stem/progenitor cells (hspcs) which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones such as skull, vertebrae, pelvis and chest. interacting factors such as stromal derived factor-1/cxcr4, very late antigen-4/vascular cell adhesion molecule-1, lymphocyte function-associated antigen-1/ intercellular adhesion molecule-1 retain the cells in the microenvironment. any factor affecting these links may lead to migration and mobilization of hspcs into peripheral blood. several factors are involved in hematopoietic stem cells (hsc) mobilization such as granulocyte-colony stimulating factor, sphingosine-1-phosphate, hepatocyte growth factor, complement system, plasminogen system and matrix metalloproteinases. in bone marrow transplantation, hsc is transferred to the recipient from bone marrow of the donor, which can be performed in two ways. in the first method, jamshidi needle is used for aspiration of bone marrow to extract hematopoietic cells usually from the hip. the second method uses mobilizer factors such as granulocyte-colony stimulating factor and granulocyte-macrophage colony-stimulating factor to mobilize the hsc into peripheral blood. mobilized hematopoietic stem cells are suitable for the bone marrow transplantation in leukemias such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocyte leukemia, hairy cell leukemia, etc.
similar resources
Advances in Hematopoietic Stem Cell Mobilization and Peripheral Blood Stem Cell Transplantation
Hematopoietic stem/progenitor cells (HSPCs) which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones such as skull, vertebrae, pelvis and chest. Interacting factors such as stromal derived factor-1/CXCR4, very late antigen-4/vascular cell adhesion molecule-1, Lymphocyte function-associated antigen-1/ intercellular adhesion molec...
full textPediatric Hematopoietic Stem Cell Transplantation
The introduction and evolution of hematopoietic stem cell transplantation (HSCT) could be traced back to 1950s, to the studies on interactions among irradiation, covering spleen and bone marrow from it and injection of bone marrow cells. Today, HSCT is considered a well-established, effective and promising means of therapy for various malignant and non-malignant medical conditions, both in chil...
full textHematopoietic Stem Cell Transplantation for Thalassemia
Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. Stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and h...
full textAdvances in hematopoietic stem cell transplantation.
Since the first successful allogenic hematopoietic stem cell transplant in 1972 by Dr. Thomas, the technique has gained importance worldwide. It has become potentially curative for many neoplastic and nonmalignant disorders. Hematopoietic stem cell transplantation (HSCT) using autologous or allogeneic hematopoietic progenitor cells has progressed and evolved because of the ability to apply new ...
full textRecent advances in hematopoietic stem cell transplantation
Hematopoietic cell transplantation (HCT), once used as a last-resort therapy, is now considered a lifesaving procedure for thousands of patients with life-threatening diseases worldwide and is frequently used early in the course of treatment for diseases destined to be uncontrollable by non-HCT therapies. Incremental advances leading to reduction of post-transplant morbidity and mortality by be...
full textAutologous Peripheral Hematopoietic Stem Cell Transplantation
From ten patients with advanced malignant disease involving the bone marrow, autologous hematopoietic stem cells were collected from the peripheral blood during eight four-hour pheresis procedures and cryopreserved. No manipulations to increase the number of stem cells circulating in the blood were used during the collections. Following marrow ablative chemotherapy or chemoradiotherapy. the aut...
full textMy Resources
Save resource for easier access later
Journal title:
مجله بین المللی علوم آزمایشگاهیجلد ۳، شماره ۱، صفحات ۱-۱۲
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023